Introduction {#S5}
============

Obesity has reached epidemic proportions in the US Hispanic population. The prevalence of obesity in Hispanics has doubled in the past 20 years with 42.5% of adults and 22.4% of children classified with obesity, increasing their risks for cardiometabolic diseases ([@R1]). The genetic influence on the transmission of obesity and its comorbidities is indisputable. Quantitative genetic analyses of body mass index (BMI), adiposity and related traits indicate heritability on the order of 0.4--0.7 ([@R2]). Genome-wide linkage and genome-wide association studies (GWAS) have identified a number of putative chromosomal regions and loci, however, they account for a small fraction and even jointly only a modest proportion of the familial risk. A recent GWAS meta-analysis of BMI in 339,224 adults identified 97 loci that accounted for about 2.7% of the BMI variation ([@R3]). Most GWAS focus on polymorphic variants with relatively high frequency; however, data are rapidly accumulating that rare variants have a large cumulative effect on normal phenotypic variation and are extremely important to complex diseases ([@R4]). Fewer GWAS have been conducted on childhood obesity ([@R5]--[@R9]). Although novel variants were identified, major common variants related to obesity overlapped to a substantial degree between children and adults. GWAS results explained only a few percent of the apparent genetic variance contributing to childhood obesity, as found in adult obesity. Furthermore, most variants found in GWAS are in the intronic or intergenic regions, making it difficult to elucidate the underlying mechanisms of obesity.

Thus, in this study, we aimed to explore the contribution of rare and common exonic variants to childhood obesity. Whole exome and whole genome sequencing are revealing the enormous extent of rare variation, much of which is unique to that individual's family ([@R4]). Major contributors to inherited disease susceptibility are likely to be alleles that arose recently in extended pedigrees ([@R10]). Purifying natural selection eliminates highly deleterious variants before they reach high frequency, therefore disease risk alleles with large effects should be enriched at lower frequencies ([@R11]).

The VIVA LA FAMILIA (VIVA) cohort was established to identify genetic variants influencing childhood obesity in the Hispanic population. Our formalized quantitative genetic analyses found the heritability of BMI and obesity-related traits to be significant ([@R1]). GWA approaches used in VIVA ([@R6]) identified specific variants related to childhood obesity; however, they did not nearly account for its high heritability indicating that a relatively large number of variants remain to be discovered. Recent advances in DNA sequencing allow us to efficiently and effectively identify both common and rare coding variants and assess their impact on obesity and associated phenotypes ([@R10]). Stop-gain, stop-loss, and a subset of non-synonymous coding variants are most likely to have direct functional consequences on disease susceptibility. In the VIVA study we take advantage of a family-based study design that will allow us to detect functional variants present at higher frequency among relatives than in the general population.

The aims of this study were 1) to generate and annotate variants from whole exome sequencing data in 928 Hispanic children from the VIVA cohort; and 2) to perform statistical analyses to identify rare as well as common variants in exonic regions associated with childhood obesity.

Methods {#S6}
=======

VIVA study participants and phenotype measurements {#S7}
--------------------------------------------------

VIVA cohort used for exome sequencing comprised 293 Hispanic families with an average family size of 5 persons (range 3 to 10) ([@R1]). All enrolled children and parents gave written informed consent or assent. The protocol was approved by the Institutional Review Boards for Human Subject Research for Baylor College of Medicine and Affiliated Hospitals and for Texas Biomedical Research Institute. Each family was ascertained on a proband with obesity between the ages 4--19 y. The VIVA cohort was highly enriched for obesity: the majority of the parents were either classified with overweight (34%) or obesity (57%) and 52% of the children were classified as with obesity. Among the obese children, 62% were above the 99^th^ BMI percentile, indicating severe obesity. Among these nuclear families, there were 32 extended family groupings, resulting in a large number of sib-pairs and first-degree cousins (1457 related-pairs).

Phenotyping has been described in detail elsewhere ([@R1], [@R6]). Briefly, the phenotyping included standard anthropometry and body composition by dual energy x-ray absorptiometry (DXA); birth weights from Texas birth records; diet by 24-h recalls; total energy expenditure and substrate utilization by 24-h room calorimetry; physical activity by accelerometry; and fasting biochemistries analyzed by standard techniques.

Whole Exome Sequencing and genome variant identification {#S8}
--------------------------------------------------------

For each DNA sample, the entire exome was captured using the custom NimbleGen VCRome 2.1 capture reagent that targets coding exons from Consensus Coding Sequence (CCDS), NCBI RNA reference sequences (RefSeq) and Vega Human Genome Annotations. Capture enrichment was followed by sequencing on Illumina platform using previously described standard protocols ([@R12]). Illumina sequence analysis was performed using the Human Genome Sequencing Center's integrated Mercury pipeline ([@R13]). Briefly, the sequencing reads were mapped to the GRCh37 human reference sequence using BWA. The Atlas suite was used to call single nucleotide variants (SNVs). Lastly, variant annotation was accomplished through the Cassandra annotation suite utilizing different databases to predict functional consequences of genomic variants and place the variants in a biological framework. Individual genotype, variant and sample level QC procedure was performed using a custom pipeline following the guidelines established for the CHARGE-S project ([@R14]). The QC procedure details are provided in the [supplement](#SD1){ref-type="supplementary-material"}.

Genotype-phenotype association analysis {#S9}
---------------------------------------

Phenotypes were transformed using the inverse normalization procedure implemented in Sequential Oligogenic Linkage Analysis Routines (SOLAR)([@R15]) and residualized using sex, age and age^2^ as covariates. For the birthweight phenotype, sex and gestational age were used as covariates in the normalization/residualization procedure. Family relationships were reconstructed and verified using Primus ([@R16]) software utilizing the SNVs from exome sequencing data. Principal component analysis was conducted using PCAir method as implemented in the GENESIS package ([@R17]). Unlike standard PCA methods (e.g. Eigenstrat), the method implemented in PCAir accounts for relatedness of the individuals and identifies PCs that accurately capture population structure and are robust to familial relatives in the sample set.

Both single variant and gene-based association analyses were conducted for 74 phenotypes using SeqMeta ([@R18]) software. Only variants on autosomal chromosomes were analyzed in this study, and all analyses used additive genetic models. The empirical pedigree information was transformed into a kinship matrix using kinship2 software ([@R19]), and included in the association analysis following the method of Chen *et al*. ([@R20]) as implemented in SeqMeta software. First ten PCs were included as covariates in the association analysis. Single variant analysis included common variants with minor allele frequency (MAF) greater or equal to 0.01. The significance level was calculated for each phenotype using Bonferroni correction, dividing the nominal significance level 0.05 by the number of SNV tests performed.

Analysis of exome data has potential to identify rare causal variants that are not genotyped in GWA studies. However, the low frequencies of rare variants will negatively impact the statistical power of an association test unless the sample size is very large. To ameliorate this problem several methods that test for the collective effect of a group of rare variants have been proposed, including burden and variance-component test. The burden tests (e.g. T1, T5 and weighted-sum method) collapse information for multiple genetic variants into a single genetic score and test for association between this score and a trait. The Sequence Kernel Association Test (SKAT), on the other hand, aggregates score test statistics of individual variants in a SNV-set to compute p-values for a gene, and is robust when variants with both positive and negative effects are included.

Gene-based analysis included rare (MAF \< 0.01), predicted protein-altering variants: stop-gain, stop-loss, missense and splice site variants. The association analysis for gene-based tests was conducted using SKAT and weighted-sums burden tests (WST) using Madsen-Browning weights (1/(MAF\*(1−MAF))). The significance level for the gene based tests was calculated using Bonferroni correction, dividing the nominal significance level 0.05 by the number of gene tests performed. This included all genes that had at least two predicted protein-altering variants, multiplied by two to account for testing with both SKAT and WST.

Results {#S10}
=======

Whole exome sequencing - identified variants {#S11}
--------------------------------------------

For the whole exome sequencing of the 928 VIVA samples, the average coverage per sample across the targeted bases by the capture design was 130X, and on average 92% of the bases targeted had at least 20X read coverage. Genotype and variant level QC analyses removed 12% of variants that did not pass our QC metrics. We removed two samples that did not pass the sample level QC metrics, and 10 samples that failed pedigree information verification. The final dataset comprised 283,587 SNVs identified in 916 samples. The dataset included 150,718 SNVs that have potential to affect the protein function, by either affecting a splice site (1,213 splice site variants), amino acid change (146,708 missense variants) or resulting in a stop gain (2,568) or stop loss (229). We identified 146,708 missense variants, of these, 123,250 were rare (MAF \<0.01) and 33,720 were predicted to be damaging by Polyphen2. A total of 31,136 missense mutations were considered rare and damaging. The frequency of SNVs shown in [Table 1](#T1){ref-type="table"} is similar to patterns and rates observed in an independent cohort ([@R21]), and demonstrates that the number of variants most likely to affect protein function (nonsense and damaging missense) is enriched in singletons and doubletons as compared to more common variants (tripletons and more). The data has been submitted to dbGAP Study Accession phs000616.

Gene-based association analysis for rare variants (MAF \< 0.01) {#S12}
---------------------------------------------------------------

Gene level association analysis for rare (MAF \< 0.01), potentially functional SNVs (stop-gain, stop-loss, splicing and missense) was performed across the 74 phenotypes using WST and SKAT. The full list of phenotypes is provided in [Table S1 (supplement)](#SD1){ref-type="supplementary-material"}. The p-value for significance was established at ≤ 1.72 × 10^−6^ based on the number of gene tests performed (29,110 tests: 14,555 genes, multiplied by two tests each). We evaluated all genes that had at least two functional, rare SNVs, and discovered 16 significant associations, three based on WST, and 13 based on SKAT ([Table 2](#T2){ref-type="table"}).

The strongest gene-based association discovered was for variants in adiponectin (***ADIPOQ***) for serum adiponectin levels (pskat = 2.1 × 10^−11^). The association was based on four rare predicted protein-altering variants (cumulative MAF = 0.009). We explored in more detail this gene-based finding by looking at the single variant level associations for each of the four underlying SNVs. The strongest single SNP association (p = 6.15 x10^−11^, effect size β = −2.7809) was for missense variant rs200573126 (p.Gly45Arg, MAF = 0.003). To investigate the contribution of other variants we removed rs200573126 from the analysis, and analyzed the remaining three variants by SKAT. The association was only nominally significant (P = 0.02), indicating that the rs200573126 variant is driving the association.

We discovered significant association of variants in cystathionine gamma-lyase (***CTH***) with serum cystathionine levels (pskat = 2.12 × 10^−7^). The association was based on five rare predicted protein-altering variants (cumulative MAF = 0.01). We explored in more detail the gene-based finding by looking at the single variant level associations for each of the five underlying SNVs. Only one variant (rs28941785, p.Thr67Ile, MAF = 0.004,) passed the nominal significance value (P = 1.7 × 10^−7^, effect size β = 1.9769). Similarly to *ADIPOQ*, we removed rs28941785 variant, and the association based on remaining SNVs was not significant (P = 0.29), indicating that the rs28941785 variant is underlying the association.

We also discovered a significant association of peroxisome biogenesis factor 1 (***PEX1***) with seven different obesity-related phenotypes. The association was based on 17 rare predicted protein-altering variants (cumulative MAF = 0.022), with the strongest association with weight for age Z-score (pskat = 2.26 × 10^−7^), followed by trunk fat mass (pskat =6.55 × 10^−7^), weight (pskat =6.59 × 10^−7^), and BMI (pskat = 1.14 × 10^−6^) ([Figure 1](#F1){ref-type="fig"}). To further investigate the association of ***PEX1*** and weight for age z-score we looked at the single variant level association results for each of the 17 rare, potentially functional variants. We discovered that only one missense variant (rs141510219, pVal734Ile, MAF = 0.005) of the 17 SNVs had nominally significant association (P = 8.97 × 10^−8^, effect size β = 1.8638) indicating that this single variant is responsible for driving the signal ([Figure 2](#F2){ref-type="fig"}). After the removal of the rs141510219 variant, and reanalysis of the seven phenotypes using SKAT, none of the seven traits met the p-value significance threshold (p-values = 0.03 -- 0.46), implicating the rs141510219 as the causal variant.

We discovered significant association (pskat = 4.23 × 10^−7^) of variants in suppressor of cytokine signaling 4 (***SOCS4***) with sleeping energy expenditure, as measured by 24-h room calorimetry. The association was based on two rare predicted protein-altering variants (cumulative MAF = 0.01). We looked at the single variant level associations for the two underlying SNVs. Only one variant (rs146421724, p.Gly54Ser, MAF = 0.0096) passed the nominal significance value (P = 3.59 × 10^−7^, effect size β = 1.4778). The complete list of significant gene-based findings, along with p-values, number of underlying SNVs and cumulative MAFs, are listed in [Table 2](#T2){ref-type="table"}.

Single variant association analysis for common variants (MAF ≥ 0.01) {#S13}
--------------------------------------------------------------------

We performed single variant association analysis for 54,360 common variants with MAF ≥ 0.01 across the 74 phenotypes. Following Bonferroni correction, we established the p-value significance level at ≤ 9.2 × 10^−7^. We discovered 16 common SNV with significant association with at least one of the phenotypes ([Table 3](#T3){ref-type="table"}). We have successfully confirmed three findings from previous VIVA GWAS studies ([@R6], [@R22], [@R23]) and report several novel associations. We have replicated association of four variants in ***SLC2A9*** with serum levels of uric acid, with the strongest association for missense variant rs16890979 (P = 6.1 × 10^−13^). We have replicated associations of missense SNV (rs12075) in ***DARC*** (P = 1.46 × 10^−27^), and missense SNV (rs58037016) in ***OR10J3*** (P = 3.2 × 10−7) with levels of monocyte chemotactic protein 1 (MCP-1). We have also confirmed the association discovered in the VIVA GWAS study, of the missense SNV (rs3733402) in ***KLKB1*** with levels of insulin-like growth factor 1 (P = 7.85 × 10^−10^). Important to note is that 87% of the samples were in common between the VIVA GWAS and this exome study, therefore *KLKB1* association is a demonstration of consistency of results across different platforms, and not an independent replication.

We discovered eight novel associations. The strongest was association of a missense variant (rs1800234, MAF = 0.041) in ***PPAR-α*** with increased diet protein levels (P = 1.05 × 10^−7^, effect size β = 0.632). We also discovered association of two synonymous SNVs (rs2236261 and rs2236260) in ***NGDN*** with an increase in respiratory quotient as measured by 24-h room calorimetry. The complete list of single SNVs that met the significance threshold, along with gene names, p-values, MAFs, and effect sizes are listed in [Table 3](#T3){ref-type="table"}.

Discussion {#S14}
==========

Whole exome sequencing revealed a novel obesity gene, ***PEX1*,** in the VIVA LA FAMILIA cohort of 916 Hispanic children. *PEX1* variants were strongly associated with multiple indices of obesity -- weight, BMI, waist circumference, fat mass and trunk fat mass. The non-synonymous SNV in *PEX1* (rs141510219) found to be responsible for the significant gene-based associations is rare (MAF = 0.005) and highly penetrant in the ten affected children from three pedigrees. These children would be classified with severe obesity based on their BMI z-scores (2.3 to 4.1) and percent fat mass (33 to 51%).

Defects in *PEX1* present a novel mechanism for the development of childhood obesity. *PEX1* is a member of the ATPase family, a large group of ATPases Associated with diverse cellular Activities (AAA). This protein is often anchored to a peroxisomal membrane and plays a role in the import of proteins into peroxisomes and *de novo* formation of peroxisomes ([@R24]). Mutations in *PEX1* are responsible for several peroxisome biogenesis disorders (PBD), with a spectrum of phenotypes from the most severe Zellweger syndrome, characterized by severe neurologic dysfunction, craniofacial abnormalities, and liver dysfunction to Heimler syndrome, at the mildest end of the PBD spectrum, characterized by hearing loss, enamel hypoplasia, and nail abnormalities.

Peroxisomes are involved in critical metabolic pathways in nearly all cells in the body required for health and development ([@R25]). *PEX* genes encode peroxins, which are proteins involved in peroxisome assembly. The peroxisome matrix of mammalian cells has over 70 enzymes required for lipid metabolism including α-, β- and ω-oxidation of fatty acids (FA), and other biochemical processes. While peroxisomal β-oxidation does not play a significant role in energy production, it does play a critical role in intermediate metabolism of bile acids, very long chain FA, pristanic acid, polyunsaturated FA, dicarboxylic FA, xenobiotics, protaglandines and leukotriens ([@R26]). Phytanic acid and pristanic acid influence transcription by activating nuclear receptors RXR-α and PPAR-α. Disruption of hypothalamic peroxisomes and reactive oxygen species (ROS) can affect central regulation of energy metabolism ([@R27]). Peroxisomal proliferation in POMC neurons by a PPAR-δ agonist decreased ROS levels and increased food intake in lean mice fed a high fat diet; the opposite occurred with PPAR-δ antagonist.

Most recently, a gene-based meta-analysis applied to the GIANT data replicated known variants (*FTO, TMEM18, MC4R, ADCY3*), but also identified six novel variants including *PEX2* for BMI, substantiating the possible role of *PEX* genes in the regulation of body weight ([@R28]). The *PEX1* variant (rs141510219) was not assayed in the GIANT GWAS study, most likely because it is a very rare variant. In the latest ExAC dataset comprising 60,706 unrelated individuals ([@R29]), the average minor allele frequency for rs141510219 was 0.00028, with the highest frequency in the Latino population (0.00139), and lower frequencies in the European population (0.00023) and others. In contrast, in our VIVA cohort this variant was present at frequency of 0.005. Although the functionality of the non-synonymous SNV in *PEX1* will require further study, the strong associations seen with obesity phenotypes in these Hispanic children and the critical metabolic pathways involving *PEX1* present a novel mechanism underlying the development of obesity. We recognize that the lack of independent replication and functional validation of the PEX1 findings are limitations of this study, but hope this result will spur further investigation of the potential link between peroxisomal biogenesis and metabolism and obesity.

Several other rare variants associated with obesity-related traits were identified. Because the genetic architecture of rare variants acting together in complex diseases is variable, we used two gene level tests to examine different scenarios ([@R30]). No gene was significant in both tests, pointing to the complementary nature, and usefulness of applying several tests because the effect and directionality of aggregated variants are not known *a priori*. Ultimately, we also found that most gene level tests were driven by one rare SNV.

Unique to the VIVA study design was the measurement of 24-h energy expenditure in room respiration calorimeters. We found that the rate of sleeping energy expenditure was significantly associated with rare variants in ***SOCS4***. The protein encoded by the *SOCS4* gene belongs to the suppressor of cytokine signaling (SOCS) protein family. Obesity is accompanied by increased proinflammatory and decreased anti-inflammatory cytokines which contribute to local and systemic inflammation and disturbances in glucose homeostasis ([@R31]). Animal studies have demonstrated the effect of proinflammatory cytokines on energy expenditure ([@R32], [@R33]). Variants in the gene ***CTH*** were associated with increased levels of plasma cystathionine. The *CTH* gene encodes a cytoplasmic enzyme that converts cystathionine into cysteine. The rs28941785 variant was associated with cystathionine levels in an exome-chip based study of the plasma metabolome ([@R34]). In VIVA, plasma cysteine was positively associated with obesity and insulin resistance, highlighting a link between the sulfur amino acid metabolic pathway and obesity and cardiometabolic risk ([@R35]). The association of rs200573126, a rare variant in the ***ADIPOQ*** gene with serum adiponectin levels has been reported previously in an exome sequencing study of Hispanic Americans ([@R36]). Previous GWAS studies have reported association of common variants in the ***ADIPOQ*** gene with adiponectin levels ([@R37]). In our exome dataset we assayed two common variants: synonymous variant rs2241766 and missense variant rs17366743, and neither was associated with adiponectin levels in the VIVA cohort.

We also identified common variants that have not been identified by previous GWAS of BMI ([@R3], [@R5]--[@R9]). A missense variant in ***PPAR-α*** was associated with dietary protein (%energy). Dietary protein (%energy) which was higher among the obese children may have been a marker for obesity ([@R38]). Respiratory quotient (RQ) was associated with two synonymous SNV in neuroguidin (***NGDN***), an EIF4E binding protein involved with the development of the vertebrate nervous system ([@R39]). In addition, we replicated previous VIVA GWAS findings for *KLKB1, DARC, OR10J3* and *SLC2A9* ([@R6], [@R22], [@R23]).

In summary, the convergence of whole exome sequencing of a large cohort, a family-based design, and extensive phenotyping resulted in the discovery of novel rare and common variants and replication of previously reported variants associated with childhood obesity. Our major finding linking *PEX1* to obesity phenotypes poses a novel mechanism of peroxisomal biogenesis and metabolism underlying the development of childhood obesity. Replication of the *PEX1* variants as well as other variants associated with related endometabolic traits and functional studies are necessary to validate these findings.

Supplementary Material {#S17}
======================
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###### 

Frequencies of SNVs in VIVA children (N=916)

  Type of Mutation                                     Singletons   Singletons (%)   Doubletons   Doubletons (%)   Triple or more   Triple or more (%)   Total
  ---------------------------------------------------- ------------ ---------------- ------------ ---------------- ---------------- -------------------- ---------
  Missense                                             40,704       **61.3**         32,944       **59.8**         73,060           **52.9**             146,708
  Nonsense                                             973          **1.5**          755          **1.4**          1,069            **0.8**              2,797
  Synonymous                                           24,712       **37.2**         21,398       **38.8**         64,002           **46.3**             110,112
  Total                                                66,389       **100**          55,097       **100**          13,8131          **100**              259,617
  **Polyphen2 missense classification**                                                                                                                  
  Benign [\*](#TFN1){ref-type="table-fn"}              22,186       **55.3**         18,158       **56.0**         47,253           **65.9**             87,597
  Possibly damaging [\*](#TFN1){ref-type="table-fn"}   6,774        **16.9**         5,615        **17.3**         10,486           **14.6**             22,875
  Probably damaging [\*](#TFN1){ref-type="table-fn"}   11,130       **27.8**         8,671        **26.7**         13,919           **19.4**             33,720
  Total [\*\*](#TFN2){ref-type="table-fn"}             40,090       **100**          32,444       **100**          71,658           **100**              144,192

Functional prediction according to Polyphen2. For variants where different splice forms had different predictions, the most damaging was chosen

Total not matching above missense count because not all variants had Polyphen2 prediction

###### 

Significant gene level associations

  Phenotype                                  Gene       SKAT p-value        WST p-value         Number of SNVs   Cumulative MAF
  ------------------------------------------ ---------- ------------------- ------------------- ---------------- ----------------
  ***Anthropometry and Body Composition***                                                                       
  Weight (kg)                                *PEX1*     **6.59 × 10^−7^**   0.4458              17               0.022
  Weight for age z-score                     *PEX1*     **2.26 × 10^−7^**   0.4275              17               0.022
  BMI (kg/m^2^)                              *PEX1*     **1.14 × 10^−6^**   0.4655              17               0.022
  BMI z-score                                *PEX1*     **1.34 × 10^−6^**   0.6811              17               0.022
  Waist circumference (cm)                   *PEX1*     **1.49 × 10^−6^**   0.3672              17               0.022
  Fat mass (kg)                              *PEX1*     **1.66 × 10^−6^**   0.6009              17               0.023
  Trunk fat mass (kg)                        *PEX1*     **6.55 × 10^−7^**   0.4814              17               0.024
  Systolic blood pressure (mmHg)             CLIC6      0.0004              **1.01 × 10^−6^**   6                0.007
  ***Energy Expenditure***                                                                                       
  Sleeping energy expenditure (kcal/d)       SOCS4      **4.23 × 10^−7^**   0.2712              2                0.01
  ***Biochemistries***                                                                                           
  Adiponectin (ng/mL)                        *ADIPOQ*   **2.1 × 10^−11^**   2.85 × 10^−5^       4                0.009
  Plasma cystathionine (μmol/L)              *CTH*      **2.12 × 10^−7^**   0.1539              5                0.01
  Free T4 (ng/dL)                            *LINGO1*   **1.6 × 10^−7^**    0.4982              4                0.01
  Serum IGF-1 free (ng/mL)                   ABI3       **8.75 × 10^−7^**   0.2054              6                0.012
  Serum IGF-1 free (ng/mL)                   SALL3      **1.32 × 10^−6^**   0.1043              4                0.007
  Urinary dopamine/creatinine ratio          *TARSL2*   3.16 × 10^−5^       **7.13 × 10^−7^**   4                0.003
  HDL (mg/dL)                                *FHDC1*    0.0241              **1.5 × 10^−6^**    23               0.04

Abbreviations: SKAT, Sequence Kernel Association Test; WST, Weighted Sums Test; SNV, single nucleotide variant; MAF, minor allele frequency; BMI, body mass index; T4, thyroxine; IGF-1, insulin-like growth factor-1; HDL, high density lipoproteins.

For each significant association both Sequence Kernel Association Test (SKAT) and Weighted Sums Test (WST) p-values are provided, with significant findings highlighted in **bold**. The number of SNVs used in the test, and the cumulative MAF is listed. Gene level significance cutoff p-value 1.72 × 10^−6^

###### 

Significant single variant level associations

  Trait                           Gene       RS ID         SNV type     p-value          Minor allele frequency   Effect size
  ------------------------------- ---------- ------------- ------------ ---------------- ------------------------ -------------
  ***Novel associations***                                                                                        
  Diet protein (% energy)         *PPARA*    rs1800234     missense     1.05 ×10^−7^     0.041                    0.632
  Total energy expenditure RQ     *NGDN*     rs2236261     synonymous   3.37 ×10^−7^     0.31                     0.274
  Total energy expenditure RQ     *NGDN*     rs2236260     synonymous   8.94 ×10^−7^     0.35                     0.258
  Serum AST (U/L)                 *CYB5R2*   rs61729556    missense     6.44 × 10^−7^    0.017                    −0.924
  Testosterone (ng/mL)            MUC21      rs112415706   missense     6.75 × 10^−7^    0.11                     −0.408
  HOMA-IR                         *UBXN11*   rs7522905     synonymous   7.04 ×10^−7^     0.40                     0.2512
  HDL (mg/dL)                     ATP1A4     rs76528638    missense     7.13 × 10^−7^    0.016                    −1.003
  Eotaxin (pg/mL)                 ACKR2      rs1366046     3′ UTR       7.25 × 10^−7^    0.34                     −0.252
  ***Replicated associations***                                                                                   
  Serum MCP-1 (pg/mL)             *DARC*     rs12075       missense     8.52 × 10^−27^   0.44                     0.533
  Serum MCP-1 (pg/mL)             *OR10J3*   rs58037016    missense     3.2 × 10^−7^     0.13                     −0.363
  Serum IGF-1 free (ng/mL)        *KLKB1*    rs3733402     missense     7.85 × 10^−10^   0.34                     −0.309
  Serum IGF-1 free (ng/mL)        *KLKB1*    rs925453      synonymous   1.68 × 10^−8^    0.26                     −0.304
  Serum uric acid (mg/dL)         *SLC2A9*   rs16890979    missense     6.1 × 10^−13^    0.39                     −0.364
  Serum uric acid (mg/dL)         *SLC2A9*   rs13125646    synonymous   1.53 × 10^−11^   0.39                     0.340
  Serum uric acid (mg/dL)         *SLC2A9*   rs13113918    synonymous   1.93 × 10^−11^   0.24                     0.387
  Serum uric acid (mg/dL)         *SLC2A9*   rs10939650    synonymous   8.42 × 10^−10^   0.32                     0.330

Abbreviations: RQ, respiratory quotient; AST, aspartate aminotransferase; HOMA-IR, homeostatic model assessment-insulin resistance; HDL, high density lipoproteins; Eotaxin, fasting serum eotaxin; MCP-1, monocyte chemotactic protein-1; IGF-1, insulin-like growth factor-1. Single variant significance cutoff p-value 9.2 × 10^−7^.

###### Study Importance

-   Genome-wide linkage and genome-wide association studies (GWAS) have identified a number of putative chromosomal regions and loci, but they account for a small fraction and even jointly only a modest proportion of the familial risk for obesity

-   convergence of whole exome sequencing, a family-based design, and extensive phenotyping resulted in discovery of novel rare and common variants associated with childhood obesity in a cohort of 928 Hispanic children

-   major finding is linking peroxisome biogenesis factor 1 (*PEX1*) to obesity phenotypes, a novel mechanism of peroxisomal biogenesis and metabolism underlying the development of childhood obesity
